Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06738225 | Serum MicroRNAs as Diagnostic Biomarkers of Colorectal Cancer | not yet recruiting | — | 80 | Bishoy ShehataOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06749015 | A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) | recruiting | — | 100 | Fudan UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06751394 |
| Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer(TRACER) |
| not yet recruiting |
| Phase 2 |
| 44 |
| Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER |
| 1 |
| Dec 27, 2024 |
| clinicaltrials |
| NCT05601505 | Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer(CINTS-R) | recruiting | Phase 2 | 470 | Peking Union Medical College HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06425133 | Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers(CARE) | recruiting | Phase 2 | 174 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06746298 | A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer | not yet recruiting | — | 118 | Shanghai Minimally Invasive Surgery CenterOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06746545 | A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer. | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 24, 2024 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05462613 | Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer(REPROGRAM-02) | recruiting | Phase 2 / Phase 3 | 446 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745700 | Impact of Behavioral Activation on Depression and Quality of Life in Patients with Colon Cancer(BAdepCa) | not yet recruiting | N/A | 400 | Region VästmanlandOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT04687631 | Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases | recruiting | Phase 3 | 508 | Fudan UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06542588 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC | recruiting | Phase 2 | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04920149 | Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome(MesaCAPP) | recruiting | Phase 2 | 150 | Ann-Sofie BackmanOTHER | 2 | Dec 17, 2024 | clinicaltrials |
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06710067 | Urine Metabolites in the Diagnosis of Disease | recruiting | — | 1,250 | Luventix, Inc.INDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT01531595 | Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer(AXOAXI) | active not recruiting | Phase 2 | 100 | Pia OsterlundOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06242418 | CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)(REVISE) | recruiting | Phase 2 | 60 | West China HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06730035 | PRediction of Outcomes and PERsonalized Radiotherapy by Biomarkers and Functional Imaging | active not recruiting | N/A | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06729736 | Implementation of the ERAS in Colorectal Cancer Patients: a Single Arm Study | enrolling by invitation | N/A | 500 | Seoul National University HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02185443 | Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases | recruiting | Phase 2 | 43 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06236373 | The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia(Survivorship) | recruiting | — | 45 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06718738 | Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer | recruiting | Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT05916040 | Total Neoadjuvant Treatment of Rectal Cancer by MRI-guided Radiotherapy(TNTRect) | recruiting | — | 35 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06710561 | The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Injectable SPN01 in Phase I. | not yet recruiting | Phase 1 | 32 | Beijing SonoPhotoNano Medical Technology Co., Ltd.OTHER | 0 | Dec 3, 2024 | clinicaltrials |
| NCT06310564 | Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy(GREENLaIT-SABR) | recruiting | N/A | 204 | IRCCS Sacro Cuore Don Calabria di NegrarOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711211 | Spanish Registry of Digestive Tumours RETUD(RETUD) | recruiting | — | 20,000 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711939 | Vocorder Device Validation in Clinical Settings - Continuous Monitoring of Individuals (Vocorder Clinical Validation-VCV)(VCV) | not yet recruiting | — | 515 | Mitera HospitalOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06405139 | Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709144 | Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer(BLARCC) | active not recruiting | Phase 3 | 896 | Haixing Ju, MDOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709885 | HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer | recruiting | Phase 2 | 100 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06710639 | Effects of Cognitive Training on Chemotherapy-Induced Cognitive Impairment in Colon Cancer Patients Undergoing Treatment(Chemobrain) in Oncology Patients With Colon Cancer Undergoing Active Treatment | not yet recruiting | N/A | 50 | University of SalamancaOTHER | 0 | Nov 29, 2024 | clinicaltrials |
| NCT05000697 | Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait(CCHOWW) | recruiting | N/A | 216 | Hospital Alemão Oswaldo CruzOTHER | 3 | Nov 27, 2024 | clinicaltrials |
| NCT06637215 | Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer | recruiting | N/A | 352 | First Hospital of China Medical UniversityOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT02754115 | An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | recruiting | — | 400 | Tata Memorial CentreOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT04999007 | Artificial Intelligence Assists Surgeons' Decision Making | recruiting | N/A | 616 | Jichao QinOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05969899 | Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer | active not recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06631443 | Asian Watch-and-Wait Database (AWWD)(AWWD) | recruiting | — | 337 | Tata Memorial CentreOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT04294264 | TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer | active not recruiting | Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05933876 | The Impact of Radiotherapy on Oligometastatic Cancer | recruiting | — | 2,000 | Institut Investigacio Sanitaria Pere VirgiliOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06690606 | EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery | not yet recruiting | — | 250 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06612281 | Evaluation of Gixam's Performance in a FIT Negative Population | recruiting | Phase 2 | 400 | Jubaan Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06688110 | Evaluation of Gixam's Efficacy Predicting Pre-cancerous Colorectal Polyps and Colorectal Cancer | not yet recruiting | N/A | 800 | Jubaan Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06411600 | Combination Therapy for BRAF-V600E Metastatic CRCm(BRAVE) | recruiting | Phase 2 | 94 | Vall d'Hebron Institute of OncologyOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03874026 | Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients(CIFRA) | recruiting | Phase 2 | 34 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04898504 | HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.(EXCALIBUR1+2) | active not recruiting | Phase 2 | 45 | Oslo University HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2024source: clinicaltrials